Professional development Vacancies

Information letter to healthcare professionals concerning the medicinal product POLIVY® (polatuzumab vedotin) powder for concentrate for solution for infusion, 140 mg; 140 mg, and 30 mg; 30 mg per vial No. 1, concerning an identified risk – severe cases of extravasation at the infusion site associated with POLIVY® (polatuzumab vedotin) – update of the section “Special warnings and precautions for use” of the instructions for medical use

10.10.2025 497 views